

Corres. and Mail BOX AF

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 3700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#18

Applicant : Carlyle et al

Serial No.: 09/014,087/

Filed : January 27, 1998

For : BIOPROSTHESIS WITH

ASSOCIATED GROWTH FACTORS

Docket No.: S16.12-0062

Group Art Unit: 3738

Examiner: P.

Prebilic

AMENDMENT AFTER FINAL

Assistant Commissioner for Patents **BOX AF**Washington, D.C. 20231

I HEREBY CERTIFY THAT THIS PAPER IS BEING SENT BY U.S. MAIL, FIRST CLASS. TO THE ASSISTANT COMMISSIONER FOR PATENTS. WASHINGTON, D.C. 20231, THIS

O3 DAY OF March . 2000.

Roton 9. Dard

PATENT ATTORNEY

Sir:

In response to the Office Action mailed on January 5, 2000, please enter the following amendments and consider the following remarks.

IN THE CLAIMS

Please amend claims 1 and 14 as follows:

1. (Twice Amended) A prosthesis for a human patient comprising allograft or kenograft tissue having a polypeptide growth factor associated therewith by a[n] biologic adhesive [or chemical binding] covalent bonding, or noncovalent bonding characteristic of antibody-antigen, specific binding protein-receptor and enzyme substrate associations, said polypeptide growth factor being effective to stimulate the affiliation of viable cells with said

tissue

14. (Twice Amended) A prosthetic heart valve comprising a substrate with associated VEGF, wherein said VEGF is associated with the substrate by direct attachment, a[n] biologic adhesive [or

DO NOCO

02